| SC 13G/A | 2024-02-14 | Deep Track Capital, LP | Travere Therapeutics, Inc. | 7,522,281 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | ARMISTICE CAPITAL, LLC | Travere Therapeutics, Inc. | 7,384,000 | 9.8% | EDGAR |
| SC 13G/A | 2024-02-14 | MACQUARIE GROUP LTD | Travere Therapeutics, Inc. | 4,746,144 | 6.3% | EDGAR |
| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Travere Therapeutics, Inc. | 5,515,143 | 7.3% | EDGAR |
| SC 13G/A | 2024-02-12 | JANUS HENDERSON GROUP PLC | Travere Therapeutics, Inc. | 32,180 | 0.0% | EDGAR |
| SC 13G | 2024-02-09 | MORGAN STANLEY | Travere Therapeutics, Inc. | 4,152,446 | 5.5% | EDGAR |
| SC 13G/A | 2024-02-07 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Travere Therapeutics, Inc. | 500,000 | 0.7% | EDGAR |
| SC 13G/A | 2024-01-25 | STATE STREET CORP | Travere Therapeutics, Inc. | - | 7.1% | EDGAR |
| SC 13G/A | 2024-01-24 | BlackRock Inc. | Travere Therapeutics, Inc. | 7,990,020 | 10.6% | EDGAR |
| SC 13G/A | 2023-10-06 | BlackRock Inc. | Travere Therapeutics, Inc. | 7,702,228 | 10.3% | EDGAR |
| SC 13G/A | 2023-05-15 | RA CAPITAL MANAGEMENT, L.P. | Travere Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2023-03-13 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Travere Therapeutics, Inc. | 4,418,962 | 5.9% | EDGAR |
| SC 13G/A | 2023-02-14 | RA CAPITAL MANAGEMENT, L.P. | Travere Therapeutics, Inc. | 3,984,681 | 6.2% | EDGAR |
| SC 13G/A | 2023-02-14 | Deep Track Capital, LP | Travere Therapeutics, Inc. | 4,582,000 | 7.1% | EDGAR |
| SC 13G/A | 2023-02-14 | ARMISTICE CAPITAL, LLC | Travere Therapeutics, Inc. | 6,412,000 | 10.0% | EDGAR |
| SC 13G/A | 2023-02-14 | MACQUARIE GROUP LTD | Travere Therapeutics, Inc. | 3,555,992 | 5.5% | EDGAR |
| SC 13G/A | 2023-02-10 | GOLDMAN SACHS GROUP INC | Travere Therapeutics, Inc. | 3,142,175 | 4.9% | EDGAR |
| SC 13G/A | 2023-02-10 | JANUS HENDERSON GROUP PLC | Travere Therapeutics, Inc. | 5,091,285 | 7.9% | EDGAR |
| SC 13G/A | 2023-02-09 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Travere Therapeutics, Inc. | 2,600,000 | 4.0% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Travere Therapeutics, Inc. | 3,515,446 | 5.5% | EDGAR |